NWBO · Northwest Biotherapeutics Inc
$0.17
0.00 (-0.69%)
At close · Jul 28
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because of recurring operating losses and operating cash flow deficits, there is substantial doubt about the Company’s ability to continue as a going concern for at least one year from the date of this filing.”View the 10-Q filed May 15, 2026
Market Cap
$282.49M
Shares
1.64B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.17
Open$0.17
Day$0.17–0.18
52W$0.14–0.37
Avg vol 30d3.1M
Short int70.0M · 4.3% float · 9.2d
Short vol24%
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−13%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−41%
trailing
YTD return
−25%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
1 of 8 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.26% of float · ▲ +2.1% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
EPS growth
+43%
Y/Y
Free cash flow
$-46.3M
Balance sheet
$57.0M
net debt
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
1 of 8 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.26% of float · ▲ +2.1% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 14%
52-wk high $0
vs 200-day avg -24%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NWBO
this stock
Northwest Biotherapeutics Inc
|
$282.49M | -25.3% | +14.8% | — | 4.3% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
8
- % held
- 0.0%
- Reported
- 1 of 8
- Top holder
- KELLEHER FINANCIAL ADVISO…
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NWBO | -4.5% | -9.5% | -40.7% | -9.5% | -25.3% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -3.5% | -9.5% | -48.2% | -8.7% | -33.9% |